Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loteprednol for post-intravitreal injection pain
NCT05542381Completed
- Sponsor
- Virginia Tech
- Start
- Dec 2022
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of loteprednol etabonate ophthalmic gel 0.38% (2 arms), sponsored by Virginia Tech. Primary endpoint: Post-Intravitreal Injection Pain at 1 week. Started Dec 2022; status: completed.
02
Drugs
loteprednol etabonate ophthalmic gel 0.38%
Beyond the preview
Go deeper on NCT05542381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05542381.